Page 3 - Societal Cost News Today : Breaking News, Live Updates & Top Stories | Vimarsana
An Interview with Mark Blaxill on the Autism Tsunami: Part 1
ageofautism.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ageofautism.com Daily Mail and Mail on Sunday newspapers.
News | City of San Jose
sanjoseca.gov - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sanjoseca.gov Daily Mail and Mail on Sunday newspapers.
Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia
Regulatory News:
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and MedinCell (Euronext: MEDCL) today announced positive results for study TV46000-CNS-30072 (the RISE study The Risperidone Subcutaneous Extended-Release Study), a Phase 3 clinical trial designed to evaluate the efficacy of TV-46000/mdc-IRM (risperidone extended-release injectable suspension for subcutaneous use) as a treatment for patients with schizophrenia. Trial enrollment was open to patients 13-65 years of age. In the RISE study, patients treated with the investigational subcutaneous risperidone injection either monthly (q1M) (n=183) or once every two months (q2M) (n=179) experienced a statistically significant delay in time to relapse versus placebo (n=181), the study s primary endpoint, with p